A novel population pharmacokinetic model for recombinant factor
IX-Fc fusion concentrate including young children with haemophilia B
Sjoerd F. Koopman1*, Tine M.H.J.
Goedhart2*, Laura H. Bukkems1,
Trevor M. Mulders1, Frank W.G.
Leebeek3, Karin Fijnvandraat4,
Michiel Coppens5,6, Mary Mathias7,
Peter W. Collins8, R. Campbell
Tait9, Catherine Bagot9, Nicola
Curry10, Jeanette Payne11, Pratima
Chowdary12, Marjon H. Cnossen2* &
Ron A.A. Mathôt1*, for the OPTI-CLOT study group and
SYMPHONY consortium.
1Hospital Pharmacy-Clinical Pharmacology, Amsterdam
University Medical Centers, Amsterdam, The Netherlands;2Department of Pediatric Hematology and Oncology,
Erasmus MC Sophia Children’s Hospital, University Medical Center
Rotterdam; Rotterdam, The Netherlands; 3Department of
Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam,
The Netherlands; 4Amsterdam UMC, University of
Amsterdam, Emma Children’s Hospital, Pediatric Hematology, Amsterdam,
The Netherlands; 5Vascular Medicine, Amsterdam UMC,
University of Amsterdam, Amsterdam, The Netherlands;6Amsterdam Cardiovascular Sciences, Pulmonary
Hypertension & Thrombosis, Amsterdam, The Netherlands;7Haemophilia Comprehensive Care Centre, Great Ormond
Street Hospital for Children NHS Foundation Trust, London, United
Kingdom; 8Arthur Bloom Haemophilia Centre, School of
Medicine, Cardiff University Hospital, Cardiff, United Kingdom;9Department of Haematology, Royal Infirmary, Glasgow,
United Kingdom; 10Oxford Haemophilia and Thrombosis
Centre and Oxford NIHR BRC, Nuffield Orthopaedic Hospital, Oxford,
United Kingdom; 11Department of Paediatric
Haematology, Sheffield Children’s NHS Foundation Trust, Sheffield,
United Kingdom; 12Katharine Dormandy Haemophilia
Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust,
London, United Kingdom
*shared first and last authorships